Carcinogenesis Advance Access published online on June 15, 2005
Carcinogenesis, doi:10.1093/carcin/bgi156
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
* To whom correspondence should be addressed. Recently we reported that the occurrence of lung adenoma caused by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was completely prevented by pretreatment of female A/J mice with 8-methoxypsoralen, a potent inhibitor of cytochrome P450 (P450 or CYP) 2A (Takeuchi et al., Cancer Res. 63:7581-7583, 2003). Thus, the aim of this study was to confirm that 8-methoxyproralen exhibits chemopreventive effects by inhibiting CYP2A in the mouse lung. The involvement of CYP2A in the metabolic activation of NNK in the lung was first evidenced by the fact that the mutagenic activation of NNK by mouse lung microsomes was inhibited by 8-methoxypsoralen, coumarin and antibodies to rat CYP2A1. Supporting this, the mutagenic activation of NNK was efficiently catalyzed by mouse CYP2A4 and CYP2A5 co-expressed with NADPH-P450 reductase in a genetically engineered Salmonnela typhimurium YG7108. The expression of mRNA for CYP2A5, but not for CYP2A4 or CYP2A12, in the mouse lung was proven by reverse transcriptase-polymerase chain reaction, probably indicating that CYP2A5 present in the mouse lung was involved in the metabolic activation of NNK. In accordance with these in vitro data, treatment of gpt delta transgenic mice with 8-methoxypsoralen prior to NNK completely inhibited the mutation of the gpt delta gene. The in vivo chemopreventive effects of 8-methoxyproralen towards NNK-induced adenoma was seen only when the agent was given to female A/J mice prior to, but not posterior to, NNK, lending support to the idea that NNK is activated by CYP2A5 in the mouse lung as an initial step to cause adenoma. The inhibition by 8-methoxypsoralen of NNK-induced adenoma was seen in a dose-dependent manner: the dose to show apparent 50% suppression was calculated to be 1.0 mg/kg. To our surprise, CYP2A protein(s) was expressed in the lesion of NNK-induced lung adenomas, probably suggesting that 8-methoxypsoralen could inhibit the possible occurrence of further mutation of the adenoma cells induced by NNK. Based on these lines of evidence, we propose that 8-methoxyproralen inhibits the CYP2A5-mediated metabolic activation of NNK in the mouse lung, leading to the prevention of NNK-induced adenoma.
Received April 2, 2005
Revised June 4, 2005
Accepted June 7, 2005
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas
2 Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
3 National Institute of Health Sciences, Tokyo 158-8501, Japan
4 Osaka City University Medical School, Osaka 545-8585, Japan
Tetsuya Kamataki, E-mail: SNC78123{at}nifty.com
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. K. Ho and R. F. Tyndale Role of CYP2A6 Genetic Variation on Smoking Behaviors and Clinical Implications ASCO Educational Book, January 1, 2008; 2008(1): 74 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. K. Siu and R. F. Tyndale Characterization and Comparison of Nicotine and Cotinine Metabolism in Vitro and in Vivo in DBA/2 and C57BL/6 Mice Mol. Pharmacol., March 1, 2007; 71(3): 826 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lee and R. F. Tyndale Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 7 - 14. [Abstract] [PDF]
|
|